Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Misses on EPS — Stock Up 0.28%

Regeneron Pharmaceuticals reported an EPS that was lower than expected, which typically raises concerns among investors. However, the stock still saw a slight increase of 0.28%, likely driven by positive sentiments around their ongoing research initiatives. Investors may be focusing on the company's long-term growth potential despite the short-term earnings miss.